Efficacy of rituximab combined with CHOP chemotherapy for 35 patients with aggressive B cell non-Hodgkin’s lymphoma
- VernacularTitle:35例利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效及其安全性
- Author:
Ying LI
;
Meijun LI
;
Ming LIAN
- Publication Type:Journal Article
- Keywords:
rituximab;
B cell non-Hodgkin’s lymphoma;
efficacy
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(12):168-170
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze efficacy of rituximab combined with chemotherapy for 35 patients with aggressive B cell non-Hodgkin’s lymphoma.Methods 70 patients with aggressive B cell non-Hodgkin’s lymphoma were chosen from Hematology Department of First Affiliated Hospital of Liaoning Medical University and divided into observation group and control group at random, each group with 35 cases.The control group were treated with CHOP chemotherapy, and the observation group were treated with anti-CD20 monoclonal antibody rituximab combined with CHOP chemotherapy. The efficacy and toxicity of two group were compared.Results The total effective rate of observation group was significantly higher than that of control group (80.0%vs.37.1%;χ2 =13.246,P<0.001).Fever cases of observation group were significantly more than those of control group (15vs.4;χ2 =8.741,P=0.003), while the other adverse reactions of leucopenia and gastrointestinal reaction between two groups were not significantly different. Conclusion For patients with aggressive B cell non-Hodgkin’s lymphoma, rituximab combined with CHOP chemotherapy has better short-term effects and its adverse reactions are tolerable, which helps patients to improve the quality of life.
